Figure 7. NAD intermediates treatment attenuates FK866-induced MSC senescence. (A) Evaluation of SA-β-gal staining and p16INK4A expression in young EP MSCs with FK866 pre-treatment in the presence of Vehicle (DMSO treated), 100 μM NAM, 100 μM NMN, 100 μM NAD, and 5 μM RSV (scale bar = 50 μm) and the quantitative analysis of the percentages of SA-β-gal positive cells and p16INK4A mRNA expression. (B, C, D) Effect of NAD intermediates treatment on NAD+ content (B) and NAD+/ NADH ratio (C), as well as Sirt1 deacetylase activity (D) after pre-treating with FK866; n = 3 independent experiments. *P < 0.05, **P < 0.01.